←
Q32 Bio Inc.193 posts
Q32 Bio Inc. avatar

Q32 Bio Inc.

@Q32Bio

Clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.

◷ Joined May 2020▧ 167 Photos and videos
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Nov 5

We’re looking forward to the 10th #DermatologyDrugDevelopmentSummit this week in Boston. Our CMO, José Trevejo, M.D., Ph.D., will share insights on the importance of standardizing global clinical trial conduct. More details below!

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Sep 30

Today we announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA trial of bempikibart in #alopeciaareata presented in a late-breaking oral and poster presentation at #EADV2026. Learn more: bit.ly/4xQ0rzJ

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Sep 28

We were honored to join the alopecia areata community in Boston at the @NAAF_Org’s Walk for Alopecia Celebration – despite the rain, we were able to convert our walk into an indoor dance party! Thank you to everyone who came out in support of people living with #alopeciaareata.

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Sep 21

Additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA trial of bempikibart in #alopeciaareata will be featured in late-breaking oral and poster presentations at #EADV2026 on Sep. 30. Learn more: bit.ly/4AmMcF4

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Sep 14

Excited to welcome José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer as we prepare to advance bempikibart into a registration-directed program for #alopeciaareata. Learn more: bit.ly/4rcLJkS

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Sep 3

It’s #AlopeciaAreata (AA) Awareness Month, a time to shed light on this disease and its impact on patients. We are advancing our lead candidate, bempikibart, a targeted biologic therapy for patients with AA.

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Jul 13

We are thrilled to announce positive 36-week topline results from Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe #alopeciaareata. Read the full press release: bit.ly/4vCbV9e

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Apr 8

We look forward to participating in the 25th Annual Needham Virtual Healthcare Conference next week. Tune in to our fireside chat on Wednesday, April 15th at 12:45 p.m. ET. Find webcast details here: bit.ly/4cv6gLv

Post attachment
Q32 Bio Inc. avatar
Q32 Bio Inc.@Q32Bio·Mar 30

Our CEO, Jodie Morrison, spoke with @BiotechTV about the ongoing Part B portion of our SIGNAL-AA clinical trial evaluating bempikibart in severe or very severe #alopeciaareata. Thanks to @bradloncar! Learn more about bempikibart and our ongoing trial: bit.ly/4sx4dMJ

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: @Q32Bio has a key phase 2 readout for its IL-7Rα in alopecia scheduled for this summer - CEO Jodie Morrison explains the science and previews it. $QTTB Full video: biotechtv.com/post/q32-bio-m…

1:46